The FDA has approved the first prescription, at-home neuromodulation therapy for individuals with major depressive disorder ...
The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under ...
CVRx, Inc. a developer of neuromodulation solutions for patients with cardiovascular diseases, announced initiation of the ...
Boston Scientific has shared a range of data highlighting the benefits of spinal cord stimulation (SCS) therapies within its ...
The FDA has approved ProlivRx, the first prescription, home-based brain neuromodulation therapy, as an adjunctive treatment ...
At booth #115, Integer will spotlight its latest advancements in neuromodulation and next-generation miniaturized active implantable medical devices (AIMDs). These innovations are designed to ...
Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today ...
Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...
ReShape Lifesciences has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application on a new Diabetes Neuromodulation system utilizing its vagal nerve block ...
For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.
Given the growing interest in non-invasive neuromodulation devices for the central nervous system, the Forum on Neuroscience and Nervous System Disorders hosted a public workshop on March 2-3, 2015 to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results